Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina.
Duke University School of Medicine, Durham, North Carolina.
Pediatr Neurol. 2018 Sep;86:66-68. doi: 10.1016/j.pediatrneurol.2018.07.016. Epub 2018 Aug 3.
Autoimmune encephalitis can result in significant neurological and psychiatric morbidity and mortality in patients of all ages and often does not respond to standard therapies. Recent reports suggest efficacy of tocilizumab, a monoclonal antibody against interleukin 6, in refractory autoimmune encephalitis.
We describe three children with refractory autoimmune encephalitis who experienced a robust, immediate clinical response following treatment with tocilizumab.
These findings support the efficacy and short-term safety of tocilizumab as a third-line treatment for refractory autoimmune encephalitis in children.
自身免疫性脑炎可导致各年龄段患者出现显著的神经和精神发病率和死亡率，且通常对标准治疗无反应。最近的报告表明，白细胞介素 6 单克隆抗体托珠单抗治疗难治性自身免疫性脑炎有效。
我们描述了 3 例难治性自身免疫性脑炎患儿，他们在接受托珠单抗治疗后立即出现了显著的临床反应。
这些发现支持托珠单抗作为难治性自身免疫性脑炎三线治疗药物的疗效和短期安全性。
